Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT04818632 Completed - Clinical trials for ER+, HER2-, Metastatic Breast Cancer

AZD9833 China PK Study

AZD9833
Start date: November 12, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Chinese patients with ER Positive, HER2 Negative, Metastatic Breast Cancer

NCT ID: NCT04818125 Completed - Breast Cancer Clinical Trials

Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.

CARMMYC
Start date: March 31, 2021
Phase: N/A
Study type: Interventional

Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood. The study will be conducted on a population of patients with breast cancer (regardless of stage of the disease and the immunohistochemical subtype). For each included patient, blood samples will be taken and tumor specimens will be collected for the study. At the end of the blood collection, the patient will have completed his participation in the study.

NCT ID: NCT04817709 Completed - Breast Carcinoma Clinical Trials

Development of a Patient Decision Aid for Women Considering Breast Reconstruction

Start date: March 20, 2017
Phase:
Study type: Observational

This study engages cancer survivors who have considered breast reconstruction after mastectomy in developing and pilot testing an up-to-date, understandable, meaningful patient decision aid video and workbook. Once the video and workbook are pilot-tested, a field test with new patients will then compare whether it is more feasible and useful for women considering breast reconstruction after mastectomy to view a video and workbook before their appointment or an educational booklet during their appointment. The video explains the process and types of reconstruction, the timeline for how breast reconstruction is done, and how the cost of this surgery is covered. The workbook helps patients compare your options and prepare for the appointment. The educational booklet explains the same process, types, timeline and costs, and is designed to help the patient and their surgeon compare and discuss the options together during the appointment. By comparing these two methods, researchers may learn which of these is more effective in helping patients make a decision about breast reconstruction.

NCT ID: NCT04813965 Completed - Breast Cancer Clinical Trials

Breast Cancer Patients' Cognitive Symptoms After Information About Chemotherapy-Related Cognitive Symptoms

CONTEXT
Start date: March 20, 2014
Phase: N/A
Study type: Interventional

Previous cross-sectional studies have shown that informing cancer patients about potential chemotherapy-related cognitive symptoms may negatively affect perceived cognitive symptoms and verbal memory performance. A multicenter, randomized study in newly diagnosed breast cancer patients receiving (neo) adjuvant chemotherapy was performed to evaluate this Adverse Information Effect (AIE) over time and investigated whether inviting patients to self-affirm can reduce such AIEs on perceived cognitive symptoms and cognitive test performance.

NCT ID: NCT04811378 Completed - Clinical trials for Breast Neoplasm Female

HaemoCerTM Application in Breast Cancer Surgery

Start date: October 5, 2017
Phase: N/A
Study type: Interventional

HaemoCer is a hemostatic agent to control bleedings during surgical procedures by accelerating natural hemostasis and is frequently applied during breast conserving surgery in women with breast cancer. There is however no adequate data available on the efficacy of HaemoCer regarding seroma formation or drainage output. The objective of this study is to investigate whether the intraoperative application of haemostatic powder (HaemoCer) in breast-conserving surgery in breast cancer patients reduces the postoperative drainage output and number of days until drain removal (number of hospitalization days).

NCT ID: NCT04807595 Completed - Breast Cancer Clinical Trials

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Start date: May 28, 2021
Phase:
Study type: Observational

This is a worldwide, multicenter, non-interventional, retrospective study of patient medical records from metastatic breast cancer (mBC) patients previously identified as human epidermal growth factor receptor 2 negative (HER2-neg), regardless of hormone status.

NCT ID: NCT04805775 Completed - Propofol Clinical Trials

Desflurane and Postoperative Sleep Quality in Patients Undergoing Elective Breast Surgery

Start date: October 21, 2021
Phase: N/A
Study type: Interventional

This study intends to investigate the effects of desflurane on postoperative sleep quality to guide perioperative patient management.

NCT ID: NCT04805736 Completed - Breast Cancer Clinical Trials

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Start date: March 25, 2021
Phase: Phase 2
Study type: Interventional

Ablative therapy, as a local treatment modality for tumors, has an immune activating effect. To explore the synergistic effect of microwave ablation combined with PD-1 inhibitors, this prospective, open-label, multi-cohort, single-center clinical study was conducted. To compare the feasibility and safety of preoperative microwave ablation alone, with or without camrelizumab in patients with early newly diagnosed breast cancer.

NCT ID: NCT04799080 Completed - Breast Cancer Clinical Trials

Chemotherapy-induced Peripheral Neuropathy (CIPN) on Motor and Sensory Function

Start date: March 6, 2021
Phase:
Study type: Observational

As cancer survival rates have been increased due to technological developments and early detection strategies, there has been been a growing need to assess the effect of long-term complications and adverse effects upon patients' functionality and quality of life. Chemotherapy, which is accepted to be the body of systemic adjuvant therapy is attributed to long-term survival, yet some side effects such as sarcopenia, loss of muscle strength and functional capacity, fatigue, and sensory disturbances due to the neurotoxic effects have been well known. Chemotherapy-induced peripheral neuropathy (CIPN) is a condition that is characterized by main loss of cutaneous sensation especially in the distal part of the extremities. CIPN affects approximately 30-40% of patients with cancer undergoing chemotherapy. Loss of sensation in distal sides of upper and lower extremities may cause not only deterioration of fine hand skills but also loss of balance and thereby one's mobility and independence are detrimentally affected. Thus, this study is aimed to assess CIPN in patients with cancer undergoing chemotherapy in a longitudinal design by assessing the cutaneous function of the sensory nerves and related effect of motor function.

NCT ID: NCT04797728 Completed - Breast Cancer Clinical Trials

Elacestrant in Preoperative Setting, a Window of Opportunity Study

ELIPSE
Start date: February 9, 2021
Phase: Early Phase 1
Study type: Interventional

ELIPSE is a window of opportunity, prospective, multicenter, phase 0 trial which evaluates the effect of Elacestrant on proliferation after 4 weeks of treatment in postmenopausal women with Estrogen Receptor-positive (ER+) and Human Epidermal Growth Factor Receptor 2-negative (HER2-negative) early breast cancer (BC) amenable to surgery.